ENLIVEN THERAPEUTICS, INC. (ELVN) P/E Ratio

Enliven Therapeutics, Inc. PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

• Enliven Therapeutics, Inc. pe ratio for the quarter ending 2026-06-30 was -35.07, a change of -23.22 year-over-year.
• Enliven Therapeutics, Inc. pe ratio for the quarter ending 2026-03-31 was -24.16, a change of -13.98 year-over-year.
• Enliven Therapeutics, Inc. pe ratio for the quarter ending 2025-12-31 was -8.82, a change of 3.55 year-over-year.
• Enliven Therapeutics, Inc. pe ratio for the quarter ending 2025-09-30 was -12.48, a change of 1.69 year-over-year.
• Enliven Therapeutics, Inc. pe ratio for fiscal 2026 was -35.07.
• Enliven Therapeutics, Inc. pe ratio for fiscal 2025 was -8.82, a change of 3.55 from fiscal 2024.
• Enliven Therapeutics, Inc. pe ratio for fiscal 2024 was -12.37, a change of -4.38 from fiscal 2023.
• Enliven Therapeutics, Inc. pe ratio for fiscal 2023 was -7.98, a change of -6.43 from fiscal 2022.